TNFRSF9 and neoplasm: Previous reports have demonstrated expansion of tumor-targeting T cell populations by culturing peripheral blood-derived T cells in the presence of either tumor-associated antigens or antibodies targeting activated T cell markers such as 41BB and programmed cell death protein 1 (PD-1).10–12 Although effective, these approaches are usually targeted towards known tumor-associated antigens and do not exploit the diversity of antigens expressed on the tumor cell surface.